| Drug Class | Company | Drug Name | Alt Name | Drug Status | Notes | AIDS# |
| Biological Response Modifier | Hemispherx; Rega Institute For Medical Research | Atvogen™ | Ampligen, AMP, Poly(I)-Poly(C12U) | Phase II | Completed |
000136
|
| Entry Inhibitor | Tobira Therapeutics | Cenicriviroc | TBR-652; TAK-652 | Phase II | Recruiting |
224423
|
| Entry Inhibitor | Tanox; Biogen Idec; Taimed Biologies | Ibalizumab | TNX-355; Hu5A8 | Phase II | Invitation Only |
209859
|
| Entry Inhibitor | Progenics Pharmaceuticals | PRO-140 | | Phase II | Ongoing |
088103
|
| Entry Inhibitor | Incyte Corporation | INCB-009471 | INCB-9471 | Phase II | Completed |
503495
|
| Entry and Fusion Inhibitors | Schering-Plough | Vicriviroc | SCH-417690, SCH-D, VCV | Phase II | Drug Development Halted as of July 15, 2010 due to poor performance |
210504
|
| Entry and Fusion Inhibitors | Genzyme Corporation | AMD-070 | AMD-11070 | Phase I/II | Completed |
495149
|
| Fusion Inhibitor | Cellegy Pharmaceuticals | Cyanovirin-N | CV-N, CV-N Protein, Cianovirina-N | Preclinical | |
045707
|
| Fusion Inhibitor | Pfizer | PF-00232798 | | Phase II | Completed |
|
| HDAC Inhibitor | Abbott Labs | Depakote™ | Valporic acid, Divalproex sodium, VPA | Phase Iib | Recruitment Unknown |
057177
|
| Integrase Inhibitor | GlaxoSmithKline | GSK1349572 | | Phase III | Recruiting |
|
| Integrase Inhibitor | Japan Tobacco Inc.; Gilead Sciences; GlaxoSmithKline | Elvitegravir | EVG, GS-9137, JTK-303 | Phase III | Ongoing |
241767
|
| Integrase Inhibitor | GlaxoSmithKline | GSK1265744 | | Phase IIa | Completed |
|
| Microbicide | Gilead Sciences | Tenofovir gel (GS-1275) | GS-1275; PMPA gel | Phase II | Completed |
021800
|
| Microbicide | Panacos Pharmaceuticals | Bevirimat | BVM, PA-457; MPC-4326 | Phase II | Completed |
028530
|
| Microbicide | Uniroyal/Crompton Corp/Biosyn | UC781 | | Phase I | Completed |
029940
|
| Microbicide | Starpharma | VivaGel™ | SPL-7013 gel | Phase II | Ongoing |
223863
|
| Microbicide | Reprotect, Inc. | BufferGel™ | Carbomer 974P, Carbopol 974P, Carbopol polymer | Phase II | Completed |
180064
|
| Microbicide | Procept/Interneuron/Indevus | Pro-2000 | PRO-2000/5 | Phase III | Completed |
032942
|
| Microbicide | Population Council Center for Biomedical Research | Carraguard™ | Carragaen, Carrageenan gum, Carrageenin, Irish moss extract, PC-515 | Phase I | Completed |
000100
|
| NNRTI | GlaxoSmithKline | GSK2248761 | IDX-899 | Phase II | On Hold |
|
| NNRTI | Janssen Pharmaceutica N.V.; Tibotec | Rilpivirine | R278474, TMC-278 | Phase III | Ongoing |
169030
|
| NNRTI | Pfizer | Lersivirine | UK453,061 | Phase II | Ongoing |
497274
|
| NNRTI | Boehringer Ingelheim | BILR 355 BS | | Phase II | Study Terminated |
212773
|
| NRTI | Achillion Pharmaceuticals | Elvucitabine | ACH-126443 | Phase II | Ongoing |
060327
|
| NRTI | Pharmasset/Dupont Pharmaceuticals; Vion | Reverset™ | Dexelvucitabine; DFC | Phase II | Study Terminated |
000572
|
| NRTI | Glaxo Wellcome; GlaxoSmithKline; Pharmasset, Inc. | Racivir | RCV; (+/-)FTC | Phase II | Completed |
005245
|
| NRTI | Biochem Pharma; Triangle Pharmaceuticals; Gilead Sciences | Amdoxovir | DAPD | Phase II | Completed |
005431
|
| Other Immune Modulator | GlaxoSmithKline | Tucaresol | | Phase II | Completed |
029800
|
| Other Immune Modulator | Cytodyn, Inc. | Cytolin™ | | Phase II | Ongoing |
|